April 21, 2016
CTI Clinical Trial & Consulting Services Announces William Irish, MSc, PhD Named Associate Editor for Clinical Transplantation
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ April 21, 2016] CTI Clinical Trial and Consulting Services (CTI) announces William Irish, MSc, PhD, Vice President, Biostatistics and Health Outcomes Research has been named Associate Editor for Clinical Transplantation, a bi-monthly journal published for those involved in the care of people who require, or have had, organ and tissue transplants. The journal has an international editorial board that includes specialists in all the major organ areas.
Dr. William Irish has over 30 years of academic and industry experience in drug development. He has been with CTI for nearly a decade, currently working in outcomes research, statistical modeling and prediction, risk assessment, competing risk analysis, clinical trial methodology, and large-scale database/claims analysis. He validated a model to predict Delayed Graft Function (DGF) in deceased donor transplants, which is used to program a web-based DGF risk calculator (www.transplantcalculator.com). In addition to his role at CTI, Irish is also Adjunct Assistant Consulting Professor in Transplant Surgery for Duke University. Prior to CTI, Irish held various positions with RTI International, SangStat Medical Corporation, and the University of Pittsburgh. He received his PhD in epidemiology from the University of Pittsburgh and his MSc in statistics from Queen’s University.
CTI is a leader in the field of transplantation, conducting more than 100 transplant projects across more than 300 investigative sites involving thousands of transplant patients, with contributions to nearly all transplant-related therapies on the market today.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com